Ketogenic diet acutely improves cognitive function in patient with Down syndrome and Alzheimer’s disease
47-year-old woman with Down syndrome presented with the complaints of fear, anxiety, confusion and memory loss.Because of her change in behavior, fear, and anxiety, she became largely housebound and struggled with fatigue, took extended naps once or twice daily, and could no longer safely be left alone for extended periods. Her primary
Should artificial intelligence be used in conjunction with Neuroimaging in the diagnosis of Alzheimer’s disease?
Dementia, or Major Neurocognitive Disorder (MND), is a general term for any disease that causes a substantial decline in at least one cognitive domain including memory, learning, executive function, and additionally, impairs an individual’s ability to perform daily tasks. Alzheimer’s disease (AD) can be divided into three stages: early-stage (mild), middle-stage (moderate), and late-stage (severe). Each phase serves to classify the development of
Lecanemab for Patients with Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial
Bayesian clinical trial designs are increasingly common; given their promotion by the US Food and Drug Administration, the future use of the Bayesian approach will only continue to increase. Innovations are possible when using the Bayesian approach
Mapping new pharmacological interventions for cognitive function in Alzheimer’s disease: a systematic review of randomized clinical trials
Alzheimer’s disease is a multifactorial progressive neurodegenerative disorder characterized by memory loss, disorientation, and gradual decline in intellectual ability. The accumulation of beta-amyloid (Aβ) peptides is assessed to be one of the essential neuropathological pillars of the disorder, and its dishomeostasis plays an essential
A Novel PSEN1 Variant Leading to Posterior Cortical Atrophy: A Case Report
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects millions of people worldwide. The disease is characterized by the deposition in the brain of amyloid-β (Aβ) plaques and neurofibrillary tangles, mainly
A Case Report of a 37-Year-Old Alzheimer’s disease Patient with Prominent Striatum Amyloid Retention
The amyloid deposition has long been considered one of the pathognomonic markers of Alzheimer’s disease (AD). Moreover, disruption in the amyloid hypothesis has been frequently discussed as an important target of intervention